News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma strengthens its organization

September 20, 2011

PledPharma AB
Company Announcement

PledPharma strengthens its organization

Stockholm, 2011-09-20 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED)
today announced that they have recruited Marie Bengtson to lead clinical
projects, and Erik Kinnman as accountable for investor relations and clinical

Marie Bengtson has 14 years of clinical development experience within the
pharmaceutical industry. This experience includes the international research
companies Merck-Serono and Sanofi-Aventis, and the world leading contract
research organization, Quintiles. Marie has considerable experience of project
management, planning, execution and reporting of clinical trials within cancer,
cardiovascular diseases, diabetes, and diseases in the nervous system. She has
been involved in early as well as late clinical trials. Moreover, she has 16
years of background as an operating room nurse. Marie most recently worked at
IRW Consulting AB, where she served as a Clinical Research Manager and Nordic
project leader. 

Erik Kinnman has 13 years of clinical experience from the pharmaceutical
industry, which includes leadership positions within AstraZeneca,
Sanofi-Synthelabo and Parke-Davies. Erik has also for several years been the
head of a life science analyst team at Danske Bank, and fund manager at Aragon
Fondkommission. Erik has earned MBA, PhD and Medical Doctor degrees, and holds
an associate professor position in experimental and clinical pain research. He
is also a board certified specialist in neurology and pain management. Erik
most recently worked at SOBI, where he was accountable for investor relations,
communication, and corporate strategy. 

”These recruitments are an important increase in PledPharma's expertise and
resources. We are approaching important clinical development milestones and the
additions of Marie and Erik to our organization are very timely. In addition,
the company's expertise within investor relations is strengthened at a point in
time when the interest for our activities are expected to increase
considerably, and thereby the need for communication with shareholders and new
investors”, commented CEO Jacques Näsström. 

For further information please contact:

Jacques Näsström, CEO, cell: +46 73 713 0979

Erik Kinnman, Investor relations, cell: +46 73 422 1540

About PledPharma

PledPharma is a Swedish specialty pharma company, focused on developing
improved treatments of life-threatening diseases. The company's products may
increase the efficiency of established therapies by reducing serious side
effects and improving quality of life. PledPharma are currently running two
phase II clinical projects with patented PLED-derivative compounds. The ability
of PLED-derivatives to reduce the side effects that arise in chemotherapy
treatment of colon cancer is examined in one of the projects, PP-095. The
possible reduction of reperfusion injuries in acute myocardial infarction
patients undergoing percutaneous coronary intervention (PCI) is evaluated in
the other project, PP-099. PledPharma (STO:PLED) is listed on NASDAQ OMX First
North. Erik Penser Bankaktiebolag is the Certified Adviser. For more
information, please visit



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10